Arlington Trust’s Halozyme HALO Stock Holding History

Arlington Trust’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14	Closed	-$728	–	628
2025 Q2	$728	Buy	+14	New	+$797	﹤0.01%	611

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Arlington Trust's HALO Position: Q3 2025 in Review

Arlington Trust sold out of Halozyme (HALO) in Q3 2025, closing a stake of 14 shares — an estimated $728 sold.

Arlington Trust first reported a position in HALO in Q2 2025 and held it in 1 quarter. The position peaked at $728 in Q2 2025. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.

Arlington Trust reported no remaining Halozyme position as of Q3 2025 after selling out during the quarter.
Arlington Trust sold 14 Halozyme shares in Q3 2025, an estimated $728.
Arlington Trust first reported a position in Halozyme in Q2 2025 and held it in 1 quarter.
Arlington Trust's Halozyme position peaked at $728 in Q2 2025.
602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.

Based on Arlington Trust's 13F filing for Q3 2025, filed 28 Oct 2025.